CIDRAP

Moderna’s 2-in-1 flu and COVID vaccine shows encouraging results in small trial

A single dose of mRNA-1073 elicited durable immune responses through 6 months against all vaccine-matched influenza and SARS-CoV-2 strains.

Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010

Refusal to review the submission is inconsistent with feedback at pre-Phase 3 and pre-submission consultations; Moderna ...

Moderna says FDA refuses to review its application for flu vaccine

Moderna noted the FDA did not identify any specific safety concerns with the vaccine and that the rejection was inconsistent ...